

CURRICULUM VITAE - Charles L. Wiseman, M.D., F.A.C.P.

Focus of Research and Areas of Interest:

Cancer Chemotherapy
Tumor Immunology and Immunotherapy
Cancer Genetics
Mathematical and Computer Modeling of Cancer

Email: CLWMD@aol.com
cw@briacell.com
wisemancharles@att.net

Website: www.briacell.com

Contact address:

Charles Wiseman, M.D., F.A.C.P.
756 Fairfield Circle
Pasadena, CA 91106
Cell Phone: 323-377-4741

Date/Place of Birth: February 8, 1944, Los Angeles, California

Military Service: 1973-75 Major, U.S. Army Medical Corps

Education:

1969 M.D., University of California at Los Angeles School of Medicine
1965 B.S., University of California at Los Angeles (Chemistry)

Board Certification:

1977 American Board of Internal Medicine – Oncology
1972 American Board of Internal Medicine - Internal Medicine

Editorial board: The Open Breast Journal (Oct 2008)

Licenses

Medical Board of California A24132 (exp 2/28/2022)
Qualified Medical Examiner 118844, (exp July 15, 2022)

BriaCell Biologics, LLC; Managing member,

BriaCell Therapeutics Corp. (BCT.V.) Founder, Director, former acting CEO (www.briacell.com);

US Corporate Headquarters 820 Heinz Ave., Suite 300; Berkeley Ca 94710

Wiseman Research Initiatives, LLC ; managing member (wisemanresearch.com)

Wiseman Cancer Research Foundation, a 501c3 public charity: President

Iris BioTech Advisory Board

Software Development Business Cooperation (Daegu City, Korea, 201000318

Professional, Research and Teaching Activities:

2014- Present	Founder and Director, Briacell Therapeutics
2006- Present	Principal, Wiseman Research Initiatives, LLC
2014- Present	Qualified Medical Evaluator State of California Department of Industrial Relations Division of Workers' Compensation Medical Unit
2000- Present	President, Wiseman Cancer Research Foundation A 501 (c) 3 non-profit fund
1994-	Private Practice, Medical Oncology
2010	Consultant, Daegu Institute of Science and Technology (Korea) Genoptix Advisory Board Iris Biotech Advisory Board
2008	Sponsor, BB-IND 10312 (PDQ ID WRI-GEV-007) Genetically- engineered Tumor Cell Vaccine for Breast and other Cancers (IRB approved 10/2008)
2005	Fmr Principal investigator, FDA BB-IND 10312 Genetically-engineered Tumor Cell Vaccine for Breast Cancer (Physician-sponsored IND)
1981-2006	Director, Immunotherapy Laboratory St. Vincent's Medical Center, Los Angeles, CA
1989-1991	Acting Chief, Division of Oncology/Hematology (Inactive) White Memorial Medical Center, Los Angeles, CA
1980-1994	Private Practice, Medical Oncology Wilshire Oncology Medical Group, Inc
1977-1980	Assistant Professor, Department of Medicine, Assistant Internist; University of Texas Comprehensive Cancer Center M. D. Anderson Hospital and Tumor Institute, Houston, TX
1977-1980	Chief, Medical Breast Division - Basic Research Program; Assistant Professor, Department of Molecular Carcinogenesis and Virology, The University of Texas System Cancer Center M.D. Anderson Hospital and Tumor Institute, Houston, TX Graduate Faculty in Virology, Graduate School of Biomedical Sciences University of Texas, Houston, TX Special Studies, Dr. Relda Cailleau – Establishment of MD-MBA Breast Cell Lines

- 1979 Clinical Consultant, Tunisian-American Breast Cancer Project
(Sponsored by the National Cancer Institute)
Tunis, Tunisia
- 1976-1977 Instructor and Assistant Internist, Department of Medicine,
Medical Breast Division (ex officio affiliate - Department of
Virology) University of Texas, Houston, TX
- 1975-1976 Advanced Senior Fellow, Department of Medicine,
University of Texas System Cancer Center,
M.D. Anderson Hospital and Tumor Institute, Houston, TX
- 1974-1975 Consultant, U.S. Veterans Administration Hospital,
Alexandria, LA
- 1972-1973 Fellowship, Oncology Department of Developmental Therapeutics
University of Texas System Cancer Center, M.D. Anderson Hospital
and Tumor Institute, Houston, TX
- 1972 Clinical Training in Neurology (Dr. S. Feldman)
Hadassah Hospital, Jerusalem, Israel
- 1970-1972 Residency, Internal Medicine, Jewish Hospital of St. Louis
Washington University Medical School Affiliated Hospitals
St. Louis, MO
- Special Studies in Pathology (see publications),
(Dr. Lauren Ackerman and Dr. K.T. Liao)
Washington University Medical School, St. Louis, MO
- 1969-1970 Internship: Medicine-Pediatrics:
University of Utah Affiliated Hospitals
Salt Lake City, UT
- 1968 Regulation of Leukocyte Alkaline Phosphatase (Dr. William Valentine)
UCLA School of Medicine, Los Angeles, CA
- 1968 Externship, Good Samaritan Hospital,
Los Angeles, CA
- 1967 Immunology of Renal Rejection
(Dr. James A. Mowbray and Dr. William Peart).
St. Mary's Hospital Medical School, London, England
- 1966 Enzymology of Amino Acid Metabolism, Pyridoxal Phosphate
(Dr. William G. Clark), UCLA School of Medicine, Los Angeles, CA
- 1962-1965 Enzymology of Phosphate Metabolism; Nucleotide Biochemistry
(Dr. Robert A. Smith, Dr. Paul D. Boyer)
UCLA Department of Chemistry, Los Angeles, CA

Awards and Honors:

Top Doctors, US News and World Report 2000-2014
Elected by his peers for inclusion in Best Doctors in America®
from 2001 to 2013
Cambridge Who's Who 2013
Fellow, American College of Physicians
President, UCLA Chapter, Student American
Medical Association
Regents Scholarship - University of California
(Medical School)
Phi Beta Kappa
Phi Lambda Epsilon (Chemistry Honorary)
Outstanding Senior in Chemistry (1965)
UCLA Regents Scholarship - University of California
(Undergraduate)

Professional Societies and Affiliations:

1994-present Chairman and Founder, Mathematics of Medical
Oncology Study Group

Medical societies, active* and inactive

American Association for Advancement of Science*
American Association for Cancer Research*
Association of Community Cancer Centers
American College of Physicians
American Society of Clinical Oncology*
American Medical Association
California Medical Association
New York Academy of Sciences
NSABP
Southwest Oncology Group
Los Angeles County Medical Association
Medical Oncology Society of Southern California
Society for Biological Therapy*
Sigma Xi

Patent Applications:

All rights transferred to Briacell Therapeutics.com

U.S. Patent 7674456 titled "Novel Breast Cancer Cell Lines
and Uses Thereof." Issued: March 9, 2010

U.S. Patent Application Number 16/110,311 filed: August 23, 2018 titled
"Whole-Cell Cancer Vaccines and Methods for Selection Thereof"
Pending

PCT Patent Application Number PCT/US2005/020137 –
filed June 8, 2005 titled "Novel Breast Cancer Cell
Lines and Uses Thereof." Pending

PCT Patent Application Number PCT/US2005/045840 –
filed December 14, 2005 titled "Novel Breast Cancer

Cell Lines and Uses Thereof." Pending

Past Community Service:

Chairman, Maimonides Society
San Gabriel Valley Division, Jewish Federation
Los Angeles, CA
Eagle Scout Recognition Program
Young Leadership Group, Jewish Federation,
Eastern Region
Board of Directors, Pasadena Jewish Temple

Publications:

Book Chapters:

1. Hortobagyi, G.N., et al., *Immunotherapy and chemo-immunotherapy of human breast cancer*, in *Immunotherapy of Human Cancer*. 1978, Raven Press: New York. p. 321-345.
2. Wiseman, C.L., *Genetics and Cancer*, in *Fundamentals of Surgical Oncology*, R.J. McKenna and G.P. Murphy, Editors. 1986, McMillan: New York. p. 66-74.
3. Wiseman, C.L. and S. Rao, *Tumor Immunology and Immunotherapy*, in *Fundamentals of Surgical Oncology*, R.J. McKenna and G.P. Murphy, Editors. 1986, McMillan: New York.
4. Wiseman, C., et al., *Clinical responses to intralymphatic whole-cell melanoma vaccine augmented by in vitro incubation with alpha-interferon*. *Ann N Y Acad Sci*, 1993. 690: p. 388-91.
5. Dyck, P., A. Bouzaglou, and C.L. Wiseman, *Malignant Brain and Spinal Cord Tumors*, in *Cancer Surgery*, R.J. McKenna and G.P. Murphy, Editors. 1994, JB Lippincott: Philadelphia.

Journal Articles:

1. Aures, D., R. Hakanson, and C. Wiseman, *Mammalian histidine decarboxylase. Activation of the apoenzyme with phospho-5'-pyridoximinotriazole*. *Eur J Pharmacol*, 1969. 8(2): p. 232-9.
2. Wiseman, C. and K.T. Liao, *Primary lymphoma of the breast*. *Cancer*, 1972. 29(6): p. 1705-12.
3. Wiseman, C., R.F. McGregor, and K.B. McCredie, *Urinary amino acid excretion in acute leukemia*. *Cancer*, 1976. 38(1): p. 219-24.
4. Ali, M.K., et al., *Electrocardiographic changes after adriamycin chemotherapy*. *Cancer*, 1979. 43(2): p. 465-71.
5. Legha, S.S., et al., *Phase II study of hexamethylmelamine alone and in combination with mitomycin C and vincristine in advanced breast carcinoma*. *Cancer Treat Rep*, 1979. 63(11-12): p. 2053-6.
6. Legha, S.S., et al., *Tamoxifen. Use in treatment of metastatic breast cancer refractory combination chemotherapy*. *Jama*, 1979. 242(1): p. 49-52.
7. Pathak, S., et al., *A human breast adenocarcinoma with chromosome and isoenzyme markers similar to those of the HeLa line*. *J Natl Cancer Inst*, 1979. 62(2): p. 263-71.
8. Yap, H.Y., et al., *Combination chemotherapy with vincristine and methotrexate for advanced refractory breast cancer*. *Cancer*, 1979. 44(1): p. 32-4.
9. Yap, H.T., et al., *Combination chemotherapy with FAC-BCG for metastatic breast cancer: impact of CMF maintenance chemotherapy*. *Cancer Treat Rep*, 1979.

10. Haq, M.M., et al., *Hepatotoxicity of hycanthone in patients with metastatic breast cancer*. *Cancer Treat Rep*, 1980. 64(8-9): p. 929-32.
11. Hortobagyi, G.N., et al., *Chemoimmunotherapy for metastatic breast cancer with 5-fluorouracil, adriamycin, cyclophosphamide, methotrexate, L-asparaginase, Corynebacterium parvum, and Pseudomonas vaccine*. *Cancer Treat Rep*, 1980. 64(1): p. 157-9.
12. Stewart, D.J., et al., *Penetration of N-(phosphonacetyl)-L-aspartate into human central nervous system and intracerebral tumor*. *Cancer Res*, 1980. 40(9): p. 3163-
13. Wiseman, C.L., C. Tiber, and G.R. Blumenschein. *Treatment of herniating subdural hematoma*. in *Jama*. 1980.
14. Wiseman, C., et al., *Autologous and homologous immunofluorescent antibody to established breast cancer cell lines*. *In Vitro*, 1980. 16(7): p. 629-33.
15. Wiseman, C.L., et al., *Human lymphocyte blastogenesis responses to mouse mammary tumor virus*. *J Natl Cancer Inst*, 1980. 64(3): p. 425-30.
16. Buzdar, A.U., et al., *Management of breast cancer patients failing adjuvant chemotherapy with adriamycin-containing regimens*. *Cancer*, 1981. 47(12): p. 2798-802.
17. Fong, K.L., et al., *Clinical pharmacology of bruceantin by radioimmunoassay*. *Cancer Chemother Pharmacol*, 1982. 9(3): p. 169-72.
18. Wiseman, C.L., et al., *Phase II trial of bruceantin in metastatic breast carcinoma*. *Am J Clin Oncol*, 1982. 5(4): p. 389-91.
19. Wiseman, C., et al., *Inflammatory breast cancer treated with surgery, chemotherapy and allogeneic tumor cell/BCG immunotherapy*. *Cancer*, 1982. 49(6): p. 1266-71.
20. Hortobagyi, G.N., et al., *Phase II evaluation of vinblastine, methotrexate, and calcium leukovorin rescue in patients with refractory metastatic breast cancer*. *Cancer*, 1983. 51(5): p. 769-72.
21. Wiseman, C., *Breast cancer and mouse mammary tumor virus (letter)*. *Ann Intern Med*, 1983. 99(3): p. 411.
22. Present, C.A., et al., *Verapamil reversal of clinical doxorubicin resistance in human cancer. A Wilshire Oncology Medical Group pilot phase I-II study*. *Am J Clin Oncol*, 1986. 9(4): p. 355-7.
23. Present, C.A., et al., *Pilot phase II trial of amphotericin B and CCNU in renal and colorectal carcinomas*. *Eur J Cancer Clin Oncol*, 1986. 22(3): p. 329-30.
24. Wiseman, C., et al., *Increased T-helper lymphocytes following active specific intralymphatic immunotherapy of cancer*. *J Biol Response Mod*, 1986. 5(5): p. 490-7.
25. Marshall, M.E., et al., *Treatment of metastatic renal cell carcinoma with coumarin (1,2-benzopyrone) and cimetidine: a pilot study*. *J Clin Oncol*, 1987. 5(6): p. 862-6.
26. Present, C.A., et al., *Human immunodeficiency virus-associated T-cell lymphoblastic lymphoma in AIDS*. *Cancer*, 1987. 60(7): p. 1459-61.
27. Present, C.A., et al., *Antiemetic effects of metoclopramide (M) continuous infusion (CI): safety, efficacy, patient preference, and cost reduction*. *Prog Clin Biol Res*, 1987. 248: p. 299-302.
28. Chia, D., et al., *The use of multiple tumor markers to monitor cancer patients. Altered Glycosylation in Tumor Cells*, 1988: p. 295-299.
29. Present, C.A., et al., *Successful imaging of human cancer with indium-111-labeled phospholipid vesicles*. *Cancer*, 1988. 62(5): p. 905-11.
30. Chia, D., et al., *Clinical application of four tumor markers in monitoring of cancer patients*. *J Tumor Marker Onco*, 1989. 4: p. 349-53.
31. Marshall, M.E., et al., *Treatment of advanced malignant melanoma with*

- coumarin and cimetidine: a pilot study. Cancer Chemother Pharmacol*, 1989. 24(1): p. 65-6.
32. Wiseman, C.L., et al., *Clinical responses with active specific intralymphatic immunotherapy for cancer--a phase I-II trial. West J Med*, 1989. 151(3): p. 283-8.
 33. Knell, E., et al., *Familial cancer genetic evaluation: introduction into a community cancer screening program. Prog Clin Biol Res*, 1990. 339: p. 361-6.
 34. Present, C.A., et al., *Human tumor fluorouracil trapping: clinical correlations of in vivo 19F nuclear magnetic resonance spectroscopy pharmacokinetics. J Clin Oncol*, 1990. 8(11): p. 1868-73.
 35. Present, C.A., et al., *Preliminary report: imaging of Kaposi sarcoma and lymphoma in AIDS with indium-111-labelled liposomes. Lancet*, 1990. 335(8701): p. 1307-9.
 36. Present, C.A., et al., *Proposed criteria for serial evaluation of quality of life in cancer patients. J Natl Cancer Inst*, 1990. 82(4): p. 322-3.
 37. Wiseman, C., et al., *OKT-3/cyclophosphamide up-regulation of peripheral blood killer-lymphocyte subsets in human cancer patients. Mol Biother*, 1991. 3(2): p. 63-7.
 38. Williams, T.W., et al., *Interleukin-2 increases the antibody response in patients receiving autologous intralymphatic tumor cell vaccine immunotherapy. Mol Biother*, 1992. 4(2): p. 66-9.
 39. Present, C.A., et al., *Association of intratumoral pharmacokinetics of fluorouracil with clinical response. Lancet*, 1994. 343(8907): p. 1184-7.
 40. Wiseman, C.L., *Inflammatory breast cancer: 10-year follow-up of a trial of surgery, chemotherapy, and allogeneic tumor cell/BCG immunotherapy. Cancer Invest*, 1995. 13(3): p. 267-71.
 41. Present, C.A., et al., *Enhancement of fluorouracil uptake in human colorectal and gastric cancers by interferon or by high-dose methotrexate: An in vivo human study using noninvasive (19)F-magnetic resonance spectroscopy. J Clin Oncol*, 2000. 18(2): p. 255-61.
 42. Kudinov, Y., C.L. Wiseman, and A.I. Kharazi, *Phorbol myristate acetate and Bryostatins 1 rescue IFN-gamma inducibility of MHC class II molecules in LS1034 colorectal carcinoma cell line. Cancer Cell Int*, 2003. 3(1):4.
 43. DePillis, L.G., A.E. Radunskaya, and C.L. Wiseman, *A validated mathematical model of cell-mediated immune responses to tumor growth; Cancer Res*. 2005; 65(17):7950-8.
 44. Wiseman, C.L., Kharazi A. *Objective clinical regression of metastatic breast cancer in disparate sites after use of whole-cell vaccine genetically modified to release sargramostim; The Breast Journal*; 2006; 12(5):475-80 (Sept 2006).
 45. Kharazi A, Y Kudinov, C Wiseman; *Interferon-alpha dose-dependent differential expression of cytokines by stimulated monocyte-derived dendritic cells; MS in progress.*
 46. Wiseman CL; *Corellation between falling CA 19-9 and survival in advanced cancer patients treated with allogeneic whole-cell tumor vaccine. MS in preparation*
 47. Wiseman CL and Kharazi A; *A Phase I study with SV-BR-1 breast cancer cell line vaccine and GM-CSF: clinical experience in 14 patients. The Open Breast Cancer Journal*; 2010; 2:4-11
 48. Wiseman CL and Radunskaya A; *Immune therapy with vaccines and surrogate correlations: questions from the fourth son. Mathematical Biosciences and Engineering* 2011; 8(2):279-87.
 49. Lacher M, Bauer G, Fury B, ...Wiseman CL and Willaims WV.; *SV-BR-1-GM, a Clinically Effective GM-CSF- Secreting Breast Cancer Cell Line, Expresses an Immune Signature and Directly Activates CD4+ T Lymphocytes; Frontiers in*

Immunology Journal; 2018; 9:776 (May 15)

50. Clinical responses and possible molecular biological mechanisms
(Submitted, *Frontiers in Immunology*. 2020)

Abstracts and Presentations:

1. Aures, D. and C.L. Wiseman. *Activation of L-histidine decarboxylase by a derivative of pyridoxal-5'-Phosphate*. in *Fed Proc Abstract*. 1967.
2. Georgiades, J.A., et al. *Infectious giant cell potentiating agent in human cells*. in *Proceedings of Annual Meeting of American Association for Cancer Research*. 1973. Southwest Section.
3. Georgiades, J.A., et al. *Immunological studies on a co-culture of cells from human osteosarcoma and peripheral white blood cells from patients with lymphocytic leukemia*. in *Proceedings of the Annual Meeting of the American Association for Cancer Research*. 1973. Southwest Section.
4. Wiseman, C.L. and R.F. McGregor. *Amino acid excretion in normal and leukemic urine*. in *Proceedings of the 66th Annual Meeting of the American Association for Cancer Research*. 1975.
5. Wiseman, C.L., et al. *A family study of reactivity to viral and mammary tumor-association*. in *Proceedings of the 67th Annual Meeting of the American Association for Cancer Research*. 1976.
6. Wiseman, C.L., et al. *Oncornavirus markers on peripheral blood lymphocytes of breast cancer patients*. in *Proceedings of the 68th Annual Meeting of the American Association for Cancer Research*. 1977.
7. Bowen, J.M., et al. *Antigenic markers in cells derived from human breast carcinoma*. in *11th Annual Meeting of Mammary Cancer in Experimental Animals and Man*. 1978. Detroit, MI.
8. Wiseman, C.L., et al. *Mitomycin-C and megestrol acetate - an active second line regimen for breast cancer patients refractory to previous treatment*. in *Proc Am Soc Clin Oncol*. 1978.
9. Harvey, H.A., et al. *Estrogen receptor status in inflammatory breast carcinoma*. in *Proc Am Soc Clin Oncol*. 1979.
10. Jordan, W.M., et al. *Importance of nutritional assessment and prechemotherapy hyperalimentation (IVH) in adenocarcinoma (ADCAR) of the lung*. in *Proc Am Soc Clin Oncol*. 1979.
11. Wiseman, C.L., J.M. Bowen, and E.M. Hersh. *Human immune response to mouse mammary tumor virus (MMTV)*. in *Proc Amer Assoc Cancer Res*. 1979.
12. Fong, K.L., et al. *Clinical pharmacology of the new antitumor agent bruceantin (BN)*. in *Proc Am Soc Clin Oncol*. 1980.
13. Wiseman, C.L., et al. *Prolonged survival of inflammatory breast cancer patients treated with combined chemoimmunotherapy and irradiation*. in *Proc Am Soc Clin Oncol*. 1980.
14. Wiseman, C.L., et al. *Cellular immune competence in inflammatory breast cancer (IBC)*. in *Proc Am Soc Clin Oncol*. 1980.
15. Wiseman, C.L., et al. *Inflammatory Breast Cancer Treatment with Surgery, Chemotherapy and Allogeneic Tumor Cell/BCC Immunotherapy*. in *Society of Surgical Oncology Annual Meeting*. 1981.
16. Wiseman, C.L., et al. *Autologous Intralymphatic Immunology - A Phase I Trial*. in *Proc Am Soc Oncol*. 1983.
17. Kennedy, P.S., et al. *Cyclophosphamide, 5-Fluorouracil, and Megestrol Acetate in Treatment of Stage D Prostate Cancer*. in *Proc Amer Soc Clin Oncol*. 1984.
18. Kennedy, P.S., et al. *Infusional Vinblastine, Cisplatin, plus CCNL in Non Small Cell*

- Lung Cancer. in Proc Amer Soc Clin Oncol. 1984.
19. Presant, C.A., et al. Verapamil plus Adriamycin - A Phase I-II Clinical Study. in Proc Amer Soc Clin Oncol. 1984.
 20. Wiseman, C.L., et al. Augmented T-Cell Subsets as a Function of Active Autologous Intralymphatic Immunotherapy in National Cancer Institute Conference on Immunity to Cancer. 1984.
 21. Gala, K.V., et al. Cyclophosphamide, 5-Fluorouracil, and Megestrol Acetate in treatment of Stage D prostate cancer. in Proc Amer Soc Clin Oncol. 1985.
 22. Presant, C.A., et al. A new method for human tumor imaging: radiolabelled lipid vesicles or liposomes. in Proc Amer Soc Clin Oncol. 1985.
 23. Presant, C., et al. Intraperitoneal and intrapleural combination chemotherapy with 5FU plus Arabinosyl Cytosine plus Cisplatinum - phase I results. in Proc Amer Assoc Cancer Res. 1985.
 24. Presant, C.A., et al. A new method for tumor imaging: radiolabelled lipid vesicles of liposomes. in European Nuclear Medicine Congress. 1985.
 25. Presant, C., et al. Human and experimental tumor with In - 111 labeled phospholipid vesicles. in 32nd Meeting, Society of Nuclear Medicine. 1985.
 26. Wiseman, C.L., et al. Active specific intralymphatic immunotherapy with or without Cyclophosphamide pre-treatment. in Proc Amer Soc Clin Oncol. 1985.
 27. Marshall, M.E., et al. Treatment of metastatic malignant melanoma with Coumarin and Cimetidine. in Proc Amer Soc Clin Oncol. 1986.
 28. Presant, C., et al. Antiemetic effects of metoclopramide (M) continuous infusion (CI): safety, patient preference, and cost reduction. in Proc Amer Soc Clin Oncol. 1986.
 29. Presant, C., et al. Duration of response and improved quality of life (QL) in Buserelin-treated prostate carcinoma: long term results. in Proc Amer Soc Clin Oncol. 1986.
 30. Rao, S., et al. Partial characterizations of two subpopulations of T4 cells induced by active specific intralymphatic immunotherapy in melanoma patients. in Proc Amer Soc Clin Oncol. 1986.
 31. Wiseman, C.L., et al. Effect of cyclophosphamide (Cy) on autologous active specific intralymphatic results. in Proc Amer Soc Clin Oncol. 1986. Los Angeles, CA.
 32. Rao, V.S., et al. Effect of cholesteryl hemisuccinate (CHS) in cell mediated immunity in melanoma patients treated with active specific intralymphatic immunotherapy (ASILI) in Proc Amer Assoc Cancer Res. 1988.
 33. Wiseman, C., et al. High dose megestrol acetate (HDM) in breast and other cancers: description of study and preliminary results. in Proc Amer Soc Clin Oncol. 1988. New Orleans, LA.
 34. Presant, C.A., et al. Tumor targeted liposomes: implications of liposomes imaging of primary and metastatic tumors for liposomal chemotherapy. in Proceedings, American Society of Clinical Oncology. 1989.
 35. Wiseman, C.L., et al. Clinical responses in autologous active specific intralymphatic immunotherapy correlate with augmentation of CD4 peripheral blood lymphocytes. in Proc Amer Soc Clin Oncol 1989.
 36. Kennedy, P., et al. Recruitment of minority patients for cancer clinical trials: Central Los Angeles CCOP Experience. in Proc Amer Soc Clin Oncol. 1990.
 37. Kennedy, P., et al. Sandostatin therapy for chemotherapy and radiotherapy related diarrhea. in Proc Amer Soc Clin Oncol. 1990.
 38. Presant, C., et al. Reduced anxiety in ambulatory oncology patients by combined education, progressive relaxation, and guided imagery; a pilot cancer control program. in Proc Amer Soc Clin Oncol. 1990.
 39. Presant, C., et al. Intratumoral T1/2 of 5FU measured by 19F magnetic resonance spectroscopy may predict for clinical anti-tumor response to 5-FU plus/minus Leucovorin. in Proc Amer Soc Clin Oncol. 1990.
 40. Wiseman, C.L., et al. Interleukin-2/active specific intralymphatic immunotherapy:

- initial clinical observations. in Proc Amer Soc Clin Oncol. 1990.
41. Wiseman, C.L., et al. Clinical pharmacology of intralymphatic IL-2. in Proc Amer Soc Clin Oncol. 1990.
 42. Wiseman, C., et al. Interleukin-2 (IL-2)/active specific intralymphatic immunotherapy (ASILI). in Society of Biological Therapy Annual Meeting. 1990. San Diego, CA.
 43. Wiseman, C.L., et al. Low-dose anti-CD3 and Cyclophosphamide: clinical and biological responses in a phase I-II trial for human cancer. in Proc Amer Soc Clin Oncol. 1991.
 44. Wiseman, C.L., et al. Can interferon make tumor vaccines more immunogenic for human melanoma and other cancers? in Proc Amer Soc Clin Oncol. 1992.
 45. Wiseman, C.L., et al. Hormonal regressions obey first-order kinetics: experience with high-dose Megestrol in breast cancer. in Proc Amer Soc Clin Oncol. 1992.
 46. Wiseman, C.L., et al. Survival in Human Melanoma and Other Cancers Treated with Autologous Intralymphatic Irradiated Tumor Cells. in 21st Meeting of the International Society for Oncodevelopmental Biology and Medicine. 1993.
 47. Wiseman, C., et al. Clinical responses of primary human CNS tumors to OKT3/cyclophosphamide. in SBT, J of Immunotherapy. 1994.
 48. Wiseman, C. and V. Hammock. Clinical experience with intralymphatic interferon-augmented melanoma vaccine and low dose cyclophosphamide. in Proc Amer Assoc Cancer Res. 1996.
 49. Arora, Y.K., et al. Establishment of pancreas cancer tissue cultures and description of ongoing trial with Vaccine/Cyclophosphamide/GMCSF for active specific immunotherapy. in SBT; J of Immunotherapy. 1997.
 50. Kharazi, A.I., et al. Tumor culture efficiency as a potential prognostic indicator in immunotherapy. in SBT; J of Immunotherapy. 1997.
Presant, C., et al., Independence of tumoral perfusion (TP) and tumoral 5-FU pharmacokinetics (PK) in determining drug response in breast cancer and other tumors (meeting abstract). J Clin Oncol, 1997. 16
 51. Wiseman, C.L., et al. Clinical responses in salvage chemoimmunotherapy for primary CNS tumors. in Proceedings, 7th International Congress of Anti-Cancer Treatment. 1997.
 52. Wiseman, C.L., et al. Response to salvage immunotherapy with anti-CD3 antibody for human glioma evaluated by volumetric analysis. in Proc Amer Soc Clin Oncol. 1997.
 53. Wiseman, C.L., et al. Salvage Monoclonal Antibody Therapy For Primary Brain Tumors. in 12th Annual Meeting SBT; J of Immunotherapy. 1997.
 54. Wiseman, C.L., et al. Response to salvage immunotherapy with anti-CD3 antibody for human glioma evaluated by volumetric analysis. in Proc Amer Soc Clin Oncol. 1997.
 55. Kharazi, A.I., et al. Differential effect of alpha and gamma interferon (IFN) melanoma on the MHC antigen expression by melanoma tissue culture vaccines. in SBT; J of Immunotherapy. 1998.
 56. Kharazi A., Arora Y., Hammock V., Berliner K., Wiseman C. Upregulation of MHC antigen expression as one of the mechanisms involved in the positive clinical response of melanoma patients to Interferon treated autologous tumor cells. 10th International Congress of Immunology, November 1-6, 1998, New Delhi, India, p.208.
 57. Kharazi, A.I., et al. Up-regulation of MHC Class I antigens as one of the mechanisms involved in positive clinical response of melanoma patients to Interferon-alpha treated autologous tumor cells. in 10th International Congress of Immunology. 1998. New Delhi, India.
 58. Kharazi, A.I., et al. Up-regulation of MHC Class I antigens as one of the mechanisms involved in positive clinical response of melanoma patients to Interferon alpha treated autologous tumor cells. in Cancer Vaccines '98 Meeting. 1998. Bethesda, MD.
 59. Kharazi, A.I., et al. Sensitivity to (Gamma-IFN) as a criterion for selection of cell lines for allegoric cell tumor vaccine treatment. in J. Immunotherapy. 1999.

60. Kudinov, Y., et al. Serum antibodies levels (AB) to sk-mel-24 cells in melanoma patients treated with intralymphatic whole-cell tumor vaccine. in *J. of Immunotherapy* 1999.
61. Kharazi, A.I., et al. Phorbol- Myristate Acetate (PMA) can potentiate Gamma-Interferon-Induced upregulation of MHC class II antigens. in *J. of Immunotherapy*. 2000.
62. Wiseman, C.L., et al. Salvage monoclonal antibody therapy for primary brain tumors. in *Proc Amer Soc Clin Oncol*. 2000.
63. Wiseman, C.L., et al. Whole-Cell/alpha-IFN-modulated pancreas cancer vaccine with GM-CSF and low-dose cyclophosphamide: initial results in 13 patients. in *SBT; J of Immunotherapy*. 2000. Berlin.
64. Kharazi, A.I., et al. Phorbol Myristate acetate can induce Gamma-Interferon dose dependent up-regulation of MHC class II antigens in poorly responding tumor cell lines. in *J. of Immunotherapy* 2001.
64. Kudinov, Y., et al. Poor response to IFN-Gamma receptors. in *Proc. 92th Annual Meeting of the American Association for Cancer Research*. 2001. New Orleans, LA.
65. Wiseman, C.L., et al. Improvement in CA 19-9 correlated with survival in pancreas patients treated with whole-cell tumor vaccine and subcutaneous GM-CSF. in *Proc Amer Soc Clin Oncol*. 2001.
66. DePillis, L.G., A.E. Radunskaya, and C.L. Wiseman. A validated computer model of the cell-mediated responses to vaccine therapy of tumor systems in the C57B/6 mouse. in *SBT, J of Immunotherapy*. 2002
67. Kudinov, Y., C.L. Wiseman, and A.I. Kharazi. MHC Class II inducibility is rescued in noninducible LS1034 colon carcinoma cell line by Bryostatin 1 and Sodium Butyrate. in *SBT, J. of Immunotherapy*. 2002.
68. Wiseman, C.L., A.I. Kharazi, and Y. Kudinov. Whole-cell tumor vaccine for human renal carcinoma: preliminary results in 14 cases. in *SBT, J. of Immunotherapy*. 2002.
69. Wiseman, C.L., et al. Whole-cell vaccine/GMCSF therapy in pancreas cancer patients; strong correlation between longer survival and decrease in CA 19-9. in *Proc Amer Soc Clin Oncol*. 2002.
70. Kharazi, A.I., et al. Effect of Interferon-Alpha on the phenotype of human monocyte-derived dendritic cells generated in the presence of GM-CSF in vitro. in *European Congress of Immunology* 2003. Rhodes, Greece.
71. Wiseman, C.L., et al. Interferon-modified whole cell intralymphatic vaccine in stage IV melanoma: results for allogeneic vs autologous preparations. in *Development of Therapeutic Cancer Vaccines* 2003. John Wayne Cancer Institute.
72. Wiseman, C.L., et al. Survey of acute hypersensitivity and autoimmune responses in 148 patients treated with intralymphatic whole-cell vaccine, low-dose Cyclophosphamide, and GMCSF. Abstract submitted to: 56th Annual Research Symposium "Cancer Immunity: Challenges for the Next Decade". 2003. M.D. Anderson (Houston, Tx).
73. Kharazi, A.I., et al. Effect of interferon-alpha on IL-10 production by the human monocyte-derived dendritic cells generated in the presence of GM-CSF in vitro. Abstract submitted to: 56th Annual Research Symposium "Cancer Immunity: Challenges for the Next Decade". 2003. M.D. Anderson (Houston, Tx).
74. Kharazi, A.I., Y. Kudinov, C.L. Wiseman, C.L. Effect of Interferon-Alpha on Differentiation of Human Monocyte-Derived Dendritic Cells In Vitro. Presentation, 12th International Congress of immunology and 4th Annual Conference of FOCIS July 18-23, 2004. Montreal, Canada. in *Clin. Invest. Med.* 2004 27(4):53C.
75. Kharazi, A.I., Y. Kudinov, C.L. Wiseman. Effect of Endogenously Produced IL-10 on Secretion of il-12p70 by Interferon-alpha Dendritic Cells. in *SBT, J. of Immunotherapy*. 2004 27(6):S24-25.
76. Wiseman, C.L., A.I. Kharazi, et al. Whole-Cell Breast Cancer Vaccine/Gmcsf: clinical

- Experience in 13 Patients with Cell Line SV-BR1. in SBT, J. of Immunotherapy.* 2004 27(6):S34-35.
77. Wiseman C.L. Kharazi, Cuevas A, Berliner K, Zagalskaya D; *Whole-cell lung cancer vaccine: clinical experience with 27 patients. Proc AACR 2005, abst 3462*
 78. Wiseman C; *Modelling of cancer regression with immunotherapy: a clinician's perspective. American Institute of Mathematics; conference on Modelling of Immune Response and Tumor Progression, Palo Alto; Dec 2005;*
 79. Wiseman CL, Kharazi A; *Regression of brain metastases in two breast cancer patients with irradiated allogeneic whole-cell vaccines, low-dose cyclophosphamide, and GM-CSF; iSBT, J. of Immunother. 2006*
 80. *Mitsuhashi M, Sutrave P, Wiseman C.; Application of real-time mRNA cytokine assay for immune monitoring of cell-mediated immune responses in breast cancer; iSBT 2009*
 81. *Wiseman CL, Kharazi AI, Selvan SR; BriaVax regressions in metastatic breast cancer: Preliminary results and description of pending clinical trial. Seventh Ann Immunother Immunomonitor Conf.;San Diego CA Jan 27, 2015*
 82. *Lacher M, Wiseman CL, Wagner, J; Molecular profile of a GM-CSF overexpressing breast cancer whole-cell vaccine with systemic anti-tumor activity; AACR 2016*
 83. *Wiseman CL, Lacher M; A Phase I/II study of the Whole-Cell Vaccine Briavax in Metastatic or Locally Recurrent Breast Cancer Patients (NCT 00095862); SABCs 2016.*
 84. *Lacher M, Graeve S, ... Wiseman CL, Peoples GE, and Williams WV. SV-BR-1-GM, a whole-cell targeted immunotherapy for advanced breast cancer: Pharmacodynamic markers of response; CRI-CIMT-EATI-AACR 2018*
 85. *Bhattacharya S, Holmes JC, Calfa C. ...Wiseman CL, Williams WV.; Initial safety and efficacy of a phase I/IIa trial of a modified whole tumor cell targeted immunotherapy in patients with advanced breast cancer; SABCs 2018*
 86. *Vivekananda (Vivek) Sunkari, Sanne Graeve, George E. Peoples, Charles L. Wiseman¹, William V. Williams, and Markus D. Lacher; Development of a personalized off-the-shelf whole-cell immunotherapy for breast cancer. AACR 2019*
 87. *William Williams, Charles L Wiseman, Shaker R. Dakhil, Jarrod P. Holmes, Saveri Bhattacharya, Carmen Calfa, Ajay Kundra, Daniel L. Adams, Diane DaSilva, George E. Peoples, Vivek Sunkari, Markus D. Lacher; Efficacy and safety of a modified whole tumor cell targeted immunotherapy in patients with advanced breast cancer alone and in combination with immune checkpoint inhibitors. SABCs 2019*
 88. *William Williams, Shaker R. Dakhil, Carmen Julia Calfa, Jarrod P. Holmes, Saveri Bhattacharya, Jason Jerome Lukas, Elizabeth Tan-Chiu, George Earl Peoples, Vivekananda Sunkari, Markus Lacher, Charles L. Wiseman; Breast cancer grade and clinical benefit in patients with advanced breast cancer treated with an engineered whole tumor cell-targeted immunotherapy alone or in combination with checkpoint inhibition. ASCO 2020*
 89. *Wiseman CL, Kharazi A, Sunkari VG, et al Regression of breast cancer metastases following treatment with SV-BR-1-GM, a GM-CSF overexpressing breast cancer cell line: clinical, molecular, and immune markers of response. Frontiers in Immunology, submitted.*